CD8A and cancer: According to recent findings, IS quantification of CD3+ and CD8+ cells on a whole digital slide section could avoid potential misclassification of cancer patients, often seen with traditional visual assessment methods.52 Therefore, standardized IS assay outperforms visual immune response assessment by expert pathologists in predicting the risk of relapse in stage II CC.51,52 These results raise the importance of implementing DP to improve cancer diagnosis and provide appropriate personalized therapeutic decisions that would critically impact patient care management in early-stage CC.51,52